LivaNova PLC (LIVN) AI Stock Analysis

LivaNova PLC designs, manufactures, and distributes therapeutic solutions worldwide across three core segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment provides oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing, and cannulae. Its Neuromodulation segment offers the VNS Therapy System, an implantable vagus nerve stimulation device treating drug-resistant epilepsy, challenging depression, and obstructive sleep apnea, while also developing the VITARIA System for heart failure. The Advanced Circulatory Support division supplies temporary life support and respiratory support systems. Products are sold globally through direct sales teams and independent distributors.

LivaNova increased revenue from $1.04B in FY2021 to $1.39B in FY2025, representing an 8.2% 5-year compound annual growth rate. Operating margin expanded from -0.1% in FY2021 to 14.4% in FY2025, though net income dropped to -$242.5M in FY2025 due to non-operating factors compared to $63.2M in FY2024. For the trailing twelve months, revenue reached $1.47B with an operating margin of 13.5% and a profit margin of 12.8%. In the latest quarter ended June 30, 2026, revenue increased 10.8% year-over-year, while quarterly earnings surged 287.8%.

As of June 30, 2026, LivaNova held $516.6M in cash and short-term investments against total debt of $351.9M, resulting in a net cash position of $164.7M. The company exhibits solid liquidity with a current ratio of 1.45 and a debt-to-equity ratio of 0.27. In FY2025, operating cash flow reached $254.3M and free cash flow stood at $173.2M. Capital deployment in FY2025 included $81.1M in capital expenditures and $4.4M directed toward share buybacks.

At $77.58, LivaNova trades at a trailing price-to-earnings multiple of 23.0x and a forward P/E of 16.0x, both lower than the median of its US-listed Healthcare peers at 24.6x and 17.3x, respectively. Its price-to-sales ratio of 2.9x is below the peer median of 4.1x, though its EV-to-EBITDA multiple of 20.0x is above the peer median of 12.0x. Over the past year, the stock returned 44.0%, outpacing the S&P 500 return of 16.8%, but its 5-year return of -7.5% lagged the broader market gain of 83.0%.

Wall Street sentiment is predominantly positive, with 6 Strong Buy, 3 Buy, and 2 Hold ratings, and no Sell ratings. The mean price target of $90.55 indicates 16.7% upside relative to the last close of $77.58. For the fiscal year ending December 31, 2026, analysts estimate EPS of $4.36 on revenue of $1.52B. LivaNova has beaten EPS estimates in each of the last 4 quarters, with its next earnings report scheduled for November 4, 2026.

This page is an AI-written research summary of LivaNova PLC (LIVN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: LIVN income statement, LIVN balance sheet, LIVN key metrics, LIVN analyst forecast, LIVN chart. See the LIVN stock overview for the latest quote and news.